Quantitative Evaluation of Safety in Drug Development -

Quantitative Evaluation of Safety in Drug Development

Design, Analysis and Reporting

Qi Jiang, H. Amy Xia (Herausgeber)

Buch | Softcover
382 Seiten
2020
Chapman & Hall/CRC (Verlag)
978-0-367-57600-4 (ISBN)
57,35 inkl. MwSt
Written by a team of experienced leaders, this book brings the most advanced knowledge and statistical methods of drug safety to the statistical, clinical, and safety community. It explains design, monitoring, analysis, and reporting issues for both clinical trials and observational studies in biopharmaceutical product development. The book addr
State-of-the-Art Methods for Drug Safety Assessment



Responding to the increased scrutiny of drug safety in recent years, Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting explains design, monitoring, analysis, and reporting issues for both clinical trials and observational studies in biopharmaceutical product development. It presents the latest statistical methods for drug safety assessment.



The book’s three sections focus on study design, safety monitoring, and data evaluation/analysis. The book addresses key challenges across regulatory agencies, industry, and academia. It discusses quantitative approaches to safety evaluation and risk management in drug development, covering Bayesian methods, effective safety graphics, and risk-benefit evaluation.



Written by a team of experienced leaders, this book brings the most advanced knowledge and statistical methods of drug safety to the statistical, clinical, and safety community. It shares best practices and stimulates further research and methodology development in the drug safety area.

Qi Jiang, PhD, is an executive director of Global Biostatistical Science at Amgen Inc. Dr. Jiang is a fellow of the American Statistical Association, a member of many industry-wide initiatives, and an associate editor of the journal Statistics in Biopharmaceutical Research (SBR). She has over 18 years of clinical trial experience in early and late clinical development phases across a broad spectrum of therapeutic areas. Her research interests include drug safety monitoring and analyses, benefit-risk assessment, clinical meaningfulness, dichotomization, meta-analyses, network meta-analysis, adaptive design, and non-inferiority study design and analyses. H. Amy Xia, PhD, is an executive director of Global Biostatistical Science at Amgen Inc. Dr. Xia is a member of many industry-wide initiatives. In the past 18 years, she has worked on designing, executing, and reporting clinical trials as well as observational studies for developing pharmaceutical and medical device products in a wide range of different disease areas. Her research interests include safety biostatistics, signal detection, Bayesian design, monitoring and analysis of clinical trials, meta-analysis, and adaptive design.

Study Design. Safety Monitoring. Evaluation/Analysis. Index.

Erscheinungsdatum
Reihe/Serie Chapman & Hall/CRC Biostatistics Series
Sprache englisch
Maße 156 x 234 mm
Gewicht 453 g
Themenwelt Mathematik / Informatik Mathematik
Medizin / Pharmazie
Naturwissenschaften Biologie
Technik
ISBN-10 0-367-57600-7 / 0367576007
ISBN-13 978-0-367-57600-4 / 9780367576004
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Von Logik und Mengenlehre bis Zahlen, Algebra, Graphen und …

von Bernd Baumgarten

Buch | Softcover (2024)
De Gruyter Oldenbourg (Verlag)
69,95
fundiert, vielseitig, praxisnah

von Friedhelm Padberg; Christiane Benz

Buch | Softcover (2021)
Springer Berlin (Verlag)
32,99